Mesoblast Ltd has released a press release.
Mesoblast Completes Resubmission of BLA to FDA for SR-aGVHD
Filed with ASX ·
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Story so far
Earlier from Mesoblast
- Extension of Undrawn US$30 million Facility
- Long-Term Survival for Acute GvHD Treatment with Remestemcel
- MSB Q1 Financial Results and Operational Highlights
- First Quarter Financial Results on Form 6-K
- Submits New Information to FDA IND File for SR-aGVHD
Later from Mesoblast
- Half Yearly Report and Accounts
- DREAM HF Trial Published in JACC
- FDA Accepts Mesoblasts BLA Resubmission for Remestemcel-L
- Voluntary Suspension
- Mesoblast Completes Private Placement
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast